Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Taletrectinib
Synonyms
Therapy Description

Ibtrozi (taletrectinib) is an inhibitor of NTRK1/2/3 and ROS1 fusion proteins, which blocks downstream signaling and may lead to inhibition of tumor cell growth (PMID: 32591465). Ibtrozi (taletrectinib) is FDA-approved for use in patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Taletrectinib Ibtrozi DS6051b|DS-6051B|DS-6051|AB-106 ROS1 Inhibitor 23 Trk Receptor Inhibitor (Pan) 33 Ibtrozi (taletrectinib) is an inhibitor of NTRK1/2/3 and ROS1 fusion proteins, which blocks downstream signaling and may lead to inhibition of tumor cell growth (PMID: 32591465). Ibtrozi (taletrectinib) is FDA-approved for use in patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ROS1 rearrange lung non-small cell carcinoma predicted - sensitive Taletrectinib Phase I Actionable In a Phase I trial, Ibtrozi (taletrectinib) demonstrated manageable toxicity, resulted in an objective response rate of 33.3% (2/6) in patients with advanced non-small cell lung cancer harboring ROS1 rearrangements (PMID: 32591465). 32591465
EML4 - ALK Advanced Solid Tumor sensitive Taletrectinib Preclinical - Cell culture Actionable In a preclinical study, cells expressing EML4-ALK were sensitive to treatment with Ibtrozi (taletrectinib) in culture, demonstrating cell growth inhibition (PMID: 31399568). 31399568
ROS1 fusion ROS1 G2032R lung non-small cell carcinoma predicted - sensitive Taletrectinib Case Reports/Case Series Actionable In a Phase II trial (TRUST-I), Ibtrozi (taletrectinib) treatment resulted in an objective response rate of 66.7% (8/12, all partial responses) in patients with non-small cell lung cancer harboring ROS1 fusions with secondary ROS1 G2032R mutations (PMID: 38822758; NCT04395677). 38822758
ROS1 fusion lung non-small cell carcinoma predicted - sensitive Taletrectinib FDA approved Actionable In a Phase II trial (TRUST-II) that supported FDA approval, Ibtrozi (taletrectinib) treatment demonstrated safety in ROS1 fusion-positive non-small cell lung cancer patients and resulted in a confirmed investigator-assessed objective response rate (cORRinv) of 94% (17/18) and a disease control rate (DCR) of 100% in the treatment-naive cohort and a cORRinv of 55% (12/22) and DCR of 91% in the previously treated cohort (Ann Oncol (2023) 34 (suppl_2):S788-S789; NCT04919811). detail... detail...
ROS1 fusion lung non-small cell carcinoma predicted - sensitive Taletrectinib Phase II Actionable In a combined analysis of 2 Phase II trials (TRUST-I, TRUST-II), Ibtrozi (taletrectinib) treatment was safe and resulted in a confirmed objective response rate (cORR) of 88.8%, a median duration of response (mDOR) of 44.2 mo, and a median progression-free survival of 45.6 mo in TKI-naive, ROS1 fusion-positive non-small cell lung cancer patients (n=160), and a cORR of 55.8%, mDOR of 16.6 mo, and mPFS of 9.7 mo in TKI-pretreated patients (n=113) (PMID: 40179330; NCT04919811, NCT04395677). 40179330
ROS1 fusion lung non-small cell carcinoma predicted - sensitive Taletrectinib Phase I Actionable In a Phase I trial, Ibtrozi (taletrectinib) was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res 2016;76(14 Suppl):Abstract nr CT024; NCT02279433). detail...
ROS1 fusion lung non-small cell carcinoma predicted - sensitive Taletrectinib FDA approved Actionable In a Phase II trial (TRUST-I) that supported FDA approval, Ibtrozi (taletrectinib) treatment resulted in a 90.6% (96/106) overall response rate (ORR) and 95.3% disease control rate (DCR) in TKI-naive non-small cell lung cancer patients with ROS1 fusions and 51.5% (34/66) ORR and 83.3% DCR in pretreated patients, intracranial ORR of 87.5% (7/8) and DCR of 100% in patients with baseline brain lesions, and partial responses in 8 of 12 patients with secondary ROS1 G2032R mutations (PMID: 38822758; NCT04395677). 38822758 detail...

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02279433 Phase I Taletrectinib A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b Completed USA 0
NCT06214793 Phase II Taletrectinib Taletrectinib in Previously Treated Metastatic CDH1-mutated Invasive Lobular Cancer (ILC) Suspended USA 0
NCT04919811 Phase II Taletrectinib Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) Recruiting USA | POL | ITA | FRA | ESP | CAN 3


Additional content available in Icon for CKB-BoostCKB BOOST